Last reviewed · How we verify
Deltyba (delamanid)
Deltyba (delamanid) is a small molecule drug class delamanid used to treat drug-resistant tuberculosis. It is a patented medication with approved indications for drug-resistant tuberculosis. Deltyba works by inhibiting the growth of Mycobacterium tuberculosis, the bacteria responsible for TB. The commercial status of Deltyba is owned by Otsuka Pharmaceutical, and its safety considerations include potential liver toxicity and gastrointestinal side effects. Deltyba is not yet off-patent.
At a glance
| Generic name | delamanid |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | delamanid |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Drug resistant tuberculosis
Common side effects
Key clinical trials
- Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB (PHASE2)
- A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets (PHASE2)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis (PHASE2)
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB (PHASE2)
- 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province (NA)
- Short-course Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2,PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |